Adicet Bio, Inc. ACET

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
50/100
Developing

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a … Full ACET analysis →

Competitive advantage assessment

Key strengths

  • Scale Supporting Profitability Profitability at scale is strong (score 0.80), demonstrating competitive advantages.
  • Operating Leverage in Effect Operating leverage is evident (score 0.85), with margins expanding over time.

Key risks

  • ROIC Below WACC or Peers ROIC at 38.3th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.07), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
42

Where ACET ranks in Biotechnology

Adicet Bio, Inc. ranks #246 of 713 scored companies in Biotechnology by moat score — the top 35%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near ACET in Biotechnology
# Company Moat score Rating
242 Bicycle Therapeutics plc BCYC 50/100 Moderate
243 Avidity Biosciences, Inc. RNA 50/100 Developing
244 Silexion Therapeutics Corp SLXN 50/100 Developing
245 Ocular Therapeutix, Inc. OCUL 50/100 Developing
246 Adicet Bio, Inc. ACET 50/100 Developing
247 Cybin Inc. CYBN 50/100 Developing
248 MediWound Ltd. MDWD 49/100 Developing
249 Agios Pharmaceuticals, Inc. AGIO 49/100 Developing
250 Palvella Therapeutics, Inc. PVLA 49/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How ACET scores on the Corporate Default defenses

Pricing Power

Score 42 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 62 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 43 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 38 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 37 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 82 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ACET's moat

What is Adicet Bio, Inc.'s moat score?

Adicet Bio, Inc. (ACET) scores 50 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #246 of 713 scored companies in Biotechnology, the top 35%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (82/100) and its weakest is Resilience (37/100).

How does Adicet Bio, Inc. compare with other Biotechnology companies?

Adicet Bio, Inc. ranks #246 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Ocular Therapeutix, Inc. (OCUL) at 50 just above it and Cybin Inc. (CYBN) at 50 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Adicet Bio, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Adicet Bio, Inc.?

The Corporate Default template measures 6 defenses, and ACET scores: Pricing Power (42), Cost Advantage (62), Customer Stickiness (43), Capital Efficiency (38), Resilience (37), Scale & Market Position (82). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000